NCT03748641 2026-03-16MAGNITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting765 enrolled 16 charts 1 FDA
NCT04497844 2026-02-13AMPLITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting696 enrolled 15 charts 1 FDA
NCT01715285 2025-02-04A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)Janssen Research & Development, LLCPhase 3 Completed1,209 enrolled 16 charts 1 FDA
NCT02987543 2023-10-06Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)AstraZenecaPhase 3 Completed387 enrolled 16 charts 2 FDA